glp-1 receptor agonists and cardiovascular outcome trials an update Effects of on cardiometabolic outcomes in heart transplant recipients: A systematic review meta-analysis of observational studies GLP-1 receptor agonists and cardiorenal
Description
10.1016/S0140-6736(18)32261-X 33 HolmanR
2020:cd190100
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al
The same manufacturer, Novo Nordisk, has another weight loss drug called Wegovy with the same active ingredient (semaglutide) that is FDA-approved for weight loss and some plans may only provide coverage for Wegovy if prescribed for weight loss and might only provide coverage for Ozempic if prescribed for diabetes
But for 2025H1, Lilly stands as the frontrunner
